Pharmacodynamics of Glycopeptides

Table of Contents

Pharmacodynamics of Glycopeptides

PPT Slide

PPT Slide

In vitro activity (MIC, mg/ml) of vancomycin, teicoplanin and oritavancin (LY333328)

Teicoplanin early failures

PPT Slide

PPT Slide

PAE and PA SME for vancomycin vs. S. aureus and S. epidermidis at 10 x MIC

PPT Slide

PPT Slide

PPT Slide

PPT Slide

Killing of S. aureus ATCC 29213 at 1 x MIC following 8 h incubation in 3 media

Glycopeptides: Protein binding and terminal half life

Mouse peritonitis model: Vancomycin and teicoplanin against ten PRP with Pen MIC´s from 0.016 to 8 mg/l

Bactericidal activity of vancomycin in bacteraemia in humans

Pharmacdynamics of glycopeptides in the mouse peritonitis model: ED50´s of different 48 h dosing regimens for vancomycin and teicoplanin against pneumococcus

PPT Slide

PPT Slide

Pharmacodynamics of glycopeptides in the mouse peritonitis model: Correlation of pk/pd parameters with effect in multidosing trial

Pharmacodynamics of glycopeptides in the mouse peritonitis model: Effect on survival of doses close to ED50

The glykopeptide pk/pd problem

Once-daily vs. Twice-daily iv vancomycin for infections in hospitalized patientsCohen et.al. JAC 2002; 49: 155-60.

Teicoplanin therapy for S. aureus septicaemiaHarding et.al. JAC 2000; 45: 835-41.

Conclusion: PK/PD for glycopeptides

Email: webmaster@isap.org

Home Page: http://www.isap.org/slides.htm

Other information:
These slides are for information only. Do not make public use of them without the autorization of their author and of ISAP. Send your requests to <webmaster@isap.org>

Download presentation as PDF file